Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 14;13(9):1831.
doi: 10.3390/v13091831.

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis

Affiliations

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis

Jennifer Wellington et al. Viruses. .

Abstract

Liver transplantation for hepatitis C virus (HCV)-related disease has the lowest five-year graft survival among all liver transplant recipients. Graft failure due to accelerated fibrosis from unrestrained HCV replication is common. Optimal timing of HCV treatment with direct-acting antiviral agents remains unknown. We compared HCV liver transplant recipients successfully treated for HCV before transplant to those treated within 1 year of transplant to determine if graft fibrosis, measured by Fib-4 scores, differs with timing of treatment. Fib-4 scores less than or equal to 1.45 defined minimal fibrosis and greater than 1.45 defined greater than minimal fibrosis. We identified 117 liver transplant recipients: 52 treated before transplantation and 65 treated within 1 year of transplantation. Overall, 34% of recipients had minimal fibrosis, and the likelihood of having minimal fibrosis following treatment and liver transplantation did not differ by timing of treatment. The odds ratio of having greater than minimal fibrosis was 0.65 (95% CI 0.30, 1.42) among those treated within 1 year after transplantation compared to those treated before transplantation (p-value 0.28). Importantly, nearly 2/3 of these patients had evidence of fibrosis progression one year after sustained virologic response, supporting recommendations for early antiviral-based treatment to prevent accumulation of HCV-related disease.

Keywords: graft fibrosis; hepatitis C Virus; liver transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Liver transplant recipient study selection. From the 263 potentially eligible patients, 117 met the inclusion criteria. Patients were divided into two groups for analysis: liver transplant recipients treated before transplant, N = 52 and liver transplant recipients treated within one year of transplant, N = 65. HCV, hepatitis C virus; DAA, direct acting antiviral therapy; UMMS, University of Maryland Medical System; PNF, primary non-function.

Similar articles

Cited by

References

    1. Kim W.R., Lake J.R., Smith J.M., Schladt D.P., Skeans M.A., Harper A.M., Wainright J.L., Snyder J.J., Israni A.K., Kasiske B.L. OPTN/SRTR 2016 Annual Data Report: Liver. Am. J. Transpl. 2018;18:172–253. doi: 10.1111/ajt.14559. - DOI - PubMed
    1. Bunchorntavakul C., Reddy K.R. Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J. Clin. Transl. Hepatol. 2014;2:124. doi: 10.14218/JCTH.2013.00002. - DOI - PMC - PubMed
    1. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896. doi: 10.1053/gast.2002.32418. - DOI - PubMed
    1. Dhanasekaran R., Sanchez W., Mounajjed T., Wiesner R.H., Watt K.D., Charlton M.R. Impact of fibrosis progression on clinical outcome in patients treated for post- transplant hepatitis C recurrence. Liver Int. 2015;35:2433–2441. doi: 10.1111/liv.12890. - DOI - PubMed
    1. Fortune B.E., Martinez-Camacho A., Kreidler S., Gralla J., Everson G.T. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl. Int. 2015;28:980–989. doi: 10.1111/tri.12568. - DOI - PMC - PubMed

Publication types

Substances